Bendamustine plus Rituximab (BR) Chemoimmunotherapy and Maintenance Lenalidomide in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): A Wisconsin Oncology Network (WON) Study

被引：0
|
作者：
Chang, Julie E. [1 ]
Zhang, Chong [2 ]
Kim, KyungMann [2 ]
Kirby, Rachel [3 ]
Volk, Lynn [3 ]
Werndli, Jae [1 ]
Go, Ronald S. [4 ]
Weiss, Matthias [5 ]
Blank, Jules H. [6 ]
Thompson, Michael A. [7 ]
Farnen, John P.
Cole, Craig E.
Bseiso, Ali W. [5 ]
Volk, Michael [6 ]
Bayer, Gerald [6 ]
Wassenaar, Tim [7 ]
Mansky, Patrick [8 ]
Traynor, Anne [1 ]
Fenske, Timothy S. [9 ]
Kahl, Brad S. [1 ]
机构：
[1] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI USA
[2] Univ Wisconsin, Dept Biostat & Med Informat, Sch Med & Publ Hlth, Madison, WI USA
[3] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA
[4] Gundersen Lutheran Hlth Syst, Ctr Canc & Blood Disorders, La Crosse, WI USA
[5] Marshfield Clin Fdn Med Res & Educ, Marshfield, WI USA
[6] St Vincent Reg Canc Ctr, Green Bay, WI USA
[7] ProHlth Care Reg Canc Ctr, Waukesha, WI USA
[8] Bellin Mem Hosp, Green Bay, WI USA
[9] Med Coll Wisconsin, Milwaukee, WI 53226 USA
来源：
BLOOD | 2012年 / 120卷 / 21期
关键词：
D O I：
10.1182/blood.V120.21.3647.3647
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3647
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Dinaciclib (SCH 727965) and Ofatumumab for the Treatment of Relapsed and Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): Results of a Phase 1b/2 Study
    Jones, Jeffrey Alan
    Geyer, Susan
    Andritsos, Leslie A.
    Awan, Farrukh
    Flynn, Joseph M.
    Maddocks, Kami J.
    Bingman, Anissa
    Johnson, Amy J.
    Heerema, Nyla A.
    Brookfield, Cathy
    Byrd, John C.
    Grever, Michael R.
    BLOOD, 2014, 124 (21)
  • [22] Sequoia: Results of a randomized phase iii trial of zanubrutinib versus bendamustine plus rituximab (br) in patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
    Greil, R.
    Robak, T.
    Giannopoulos, K.
    Jurczak, W.
    Simkovic, M.
    Shadman, M.
    Oesterborg, A.
    Laurenti, L.
    Walker, P.
    Opat, S.
    Chan, H.
    Ciepluch, H.
    Tani, M.
    Trneny, M.
    Brander, D. M.
    Flinn, I. W.
    Grosicki, S.
    Verner, E.
    Brown, J. R.
    Kahl, B. S.
    Ghia, P.
    Li, J.
    Tian, T.
    Zhou, L.
    Marimpietri, C.
    Paik, J. C.
    Cohen, A.
    Hillmen, P.
    Tam, C. S.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 117 - 118
  • [23] Acalabrutinib vs Rituximab Plus Idelalisib (IdR) or Bendamustine (BR) by Investigator Choice in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia: Phase 3 ASCEND Study
    Ghia, Paolo
    Pluta, Andrzej
    Wach, Malgorzata
    Lysak, Daniel
    Kozak, Tomas
    Simkovic, Martin
    Kaplan, Polina
    Kraychok, Iryna
    Illes, Arpad
    De La Serna, Javier
    Dolan, Sean
    Campbell, Phillip
    Musuraca, Gerardo
    Jacob, Abraham
    Avery, Eric J.
    Lee, Jae Hoon
    Liang, Wei
    Patel, Priti
    Quah, Cheng
    Jurczak, Wojciech
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S280 - S281
  • [24] UPDATED RESULTS OF A PHASE II STUDY OF LENALIDOMIDE AND RITUXIMAB IN RELAPSED/REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA.
    Piris-Villaespesa, M.
    Chavez, J.
    Dalia, S.
    Veliz, M.
    Lancet, Jeffrey
    Bello, C.
    Turba, E.
    Shah, B.
    Komrokji, R.
    Sokol, L.
    Locke, F.
    Kharfan-Dabaja, M.
    Sotomayor, E.
    Pinilla-Ibarz, J.
    HAEMATOLOGICA, 2013, 98 : 46 - 46
  • [25] Alpine: Phase 3 Trial of Zanubrutinib (BGB-3111) Vs Ibrutinib in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
    Hillmen, Peter
    Brown, Jennifer R.
    Byrd, John C.
    Eichhorst, Barbara F.
    Lamanna, Nicole
    O'Brien, Susan M.
    Qiu, Lugui
    Salmi, Tommi
    Hilger, James
    Huang, Jane
    Tam, Constantine S.
    BLOOD, 2019, 134
  • [26] Ibrutinib (I) plus bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): a 2-year follow-up of the HELIOS study.
    Fraser, Graeme
    Cramer, Paula
    Demirkan, Fatih
    Silva, Rodrigo Santucci
    Pylypenko, Halyna
    Grosicki, Sebastian
    Janssens, Ann
    Pristupa, Aleksander
    Mayer, Jiri
    Dilhuydy, Marie-Sarah
    Loscertales, Javier
    Goy, Andre
    Avigdor, Abraham
    Rule, Simon
    Phelps, Charles
    Mahler, Michelle
    Salman, Mariya
    Howes, Angela J.
    Balasubramanian, Sriram
    Chanan-Khan, Asher Alban Akmal
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [27] SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib Versus Bendamustine plus Rituximab (BR) in Patients With Treatment-Naive (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
    Kahl, Brad S.
    Giannopoulos, Krzysztof
    Jurczak, Wojciech
    Simkovic, Martin
    Shadman, Mazyar
    Osterborg, Anders
    Laurenti, Luca
    Walker, Patricia
    Opat, Stephen
    Chan, Henry
    Ciepluch, Hanna
    Greil, Richard
    Tani, Monica
    Trneny, Marek
    Brander, Danielle M.
    Flinn, Ian W.
    Grosicki, Sebastian
    Verner, Emma
    Brown, Jennifer R.
    Ghia, Paolo
    Li, Jianyong
    Tian, Tian
    Zhou, Lei
    Marimpietri, Carol
    Paik, Jason C.
    Cohen, Aileen
    Robak, Tadeusz
    Hillmen, Peter
    Tam, Constantine S.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S269 - S270
  • [28] SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib versus Bendamustine plus Rituximab (BR) in Patients with Treatment-Naive (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
    Tam, Constantine S.
    Giannopoulos, Krzysztof
    Jurczak, Wojciech
    Simkovic, Martin
    Shadman, Mazyar
    Osterborg, Anders
    Laurenti, Luca
    Walker, Patricia
    Opat, Stephen
    Chan, Henry
    Ciepluch, Hanna
    Greil, Richard
    Tani, Monica
    Trneny, Marek
    Brander, Danielle M.
    Flinn, Ian W.
    Grosicki, Sebastian
    Verner, Emma
    Brown, Jennifer R.
    Kahl, Brad S.
    Ghia, Paolo
    Tian, Tian
    Marimpietri, Carol
    Paik, Jason C.
    Cohen, Aileen
    Huang, Jane
    Robak, Tadeusz
    Hillmen, Peter
    BLOOD, 2021, 138
  • [29] Lenalidomide and Rituximab Maintenance Therapy after Front-Line Induction Chemoimmunotherapy in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
    Chang, Julie E.
    Kenkre, Vaishalee P.
    Fletcher, Christopher D.
    Hall, Aric C.
    Callander, Natalie Scott
    Kim, Kyungmann
    Chen, Grace Yi
    Chambers, Kaitlin
    BLOOD, 2019, 134
  • [30] Ibrutinib combined with bendamustine/rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): subgroup efficacy analyses from the HELIOS trial
    Fraser, Graeme
    Chanan-Khan, Asher
    Cramer, Paula
    Demirkan, Fatih
    Silva, Rodrigo Santucci
    Pylypenko, Halyna
    Grosicki, Sebastian
    Janssens, Ann
    Pristupa, Aleksander
    Goy, Andre
    Mayer, Jiri
    Dilhuydy, Marie-Sarah
    Loscertales, Javier
    Bartlett, Nancy
    Avigdor, Abraham
    Rule, Simon
    Sun, Steven
    Phelps, Charles
    Mahler, Michelle
    Salman, Masha
    Howes, Angela
    Hallek, Michael
    LEUKEMIA & LYMPHOMA, 2015, 56 : 98 - 100
12345